LFB is a French biopharmaceuticals company specialising in therapeutic proteins.
5th largest company in the field of plasma-derived medicinal products worldwide, LFB is a leader in France in this area, and features among the major European biotechnologies stakeholders. A recognized expert in immunology, intensive care and haemostasis, LFB develops, manufactures and sells medicinal products for the treatment of diseases always serious and often rare. LFB has expertise in biological medicinal products. Its developments focus on creating advanced therapies that aim to meet essential public health requirements. Each year, significant investment is made in research and development. LFB's commitment to the treatment of rare diseases is one of the company's long-standing cornerstones of its activity.
LFB is a French biopharmaceutical company, the head office of which is located in France, where 80% of the company's activity takes place. The group has witnessed significant growth abroad over the last few years, with a nearly 60% increase in our international turnover, in 2012, through an asserted desire to develop worldwide, thanks to its medicinal products of high therapeutic potential and thanks to the development of its industrial and pharmaceutical know-how.
LFB in FranceIn France, LFB is a stakeholder in plasma-derived medicinal products for protecting public health. French legislation* provides for LFB to supply French hospitals with plasma-derived medicinal products made in France as a priority. In return, LFB has exclusive rights over fractionation of plasma collected in France by the Etablissement Français du Sang (EFS). LFB's role as public health stakeholder in France is demonstrated in its obligation to supply French hospitals as a priority, thus ensuring a constant and regular supply of essential proteins.
* 2009 Hôpitaux, Patients, Santé, Territoires (HPST-Hospitals, Patients, Health and Territories) law